S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Caribou Biosciences , Inc. (NASDAQ:CRBU), currently trading near its 52-week low of $1.22 and down over 80% in the past year, recently disclosed that its Chief Scientific Officer, Steven Kanner, sold shares worth $4,811. The transaction took place on February 21, 2025, where Kanner sold 3,564 shares at an average price of $1.35 per share. This sale was conducted to cover tax obligations related to the vesting of restricted stock units (RSUs), and not as a discretionary trade. According to InvestingPro analysis, the company appears undervalued at its current market cap of $118 million.
In addition to the sale, Kanner acquired 37,500 common shares on February 20, 2025, as part of a restricted stock unit grant. These RSUs will vest over four years, starting February 20, 2026, contingent upon Kanner’s continued service with the company. The company maintains a strong liquidity position with a current ratio of 7.38, indicating ample resources to meet its obligations.
Moreover, Kanner was granted an option to purchase 170,000 shares of common stock at an exercise price of $1.41 per share. This option will vest over a four-year period beginning February 20, 2026. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed reports covering 13 additional key metrics and trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.